We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.00 | -0.15% | 1,333.00 | 1,333.00 | 1,334.00 | 1,337.50 | 1,333.00 | 1,335.00 | 350,393 | 09:20:46 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.22 | 55.34B |
Date | Subject | Author | Discuss |
---|---|---|---|
22/2/2022 11:06 | That's $100bn, not £'s, not such a dream, but reflects what some experts believe the standalone entity to reach ...... ;0) | tradermichael | |
22/2/2022 10:45 | 100bn dreamland | spoole5 | |
22/2/2022 09:36 | OK, how about Beecham Healthcare? | tradermichael | |
22/2/2022 09:27 | How about GSK Consumer Healthcare? | tradermichael | |
22/2/2022 09:19 | I was thinking Microsoft Consumer Healthcare. | suresure | |
22/2/2022 09:17 | spoole5 - GSK and Pfizer would have opened negotiations with Unilever's boss Alan Jope if the consumer goods giant was ready to improve its bid to more than 60 billion pounds, a source familiar with Pfizer's strategy said. The source called the business a "legitimate standalone candidate", adding its market value could rise to almost $100 billion once the business was spun out and listed. | tradermichael | |
22/2/2022 09:14 | Unilever consumer health?! | spoole5 | |
22/2/2022 09:11 | So if I got 1000 shares now when it splits will I get 500 shares in each of the new companies. | csalvage | |
22/2/2022 09:08 | New name reveal today for CH business. Any guesses? | suresure | |
22/2/2022 09:02 | Really will be fascinating to see the valuation the consumer side achieves post split. Bet it won't be anywhere near 50bn. That aside I'm sure there will be some handsome share option coming the way of executives! | spoole5 | |
22/2/2022 07:44 | What I dont get, is why do these moaners stay here month after month moaning? Why dont they simply move to a different company? What on earth is going on? Are the moaners nutters? | netcurtains | |
21/2/2022 22:30 | She is a failure pure and simple, and they are trusting her to run the pharma side post split. | spoole5 | |
21/2/2022 18:13 | Not given yet. Should get more info on GSK's Consumer Healthcare Capital Markets Day, next Monday 28th Feb | jonjoneil | |
21/2/2022 17:33 | When is the split up | stevenrevell | |
21/2/2022 16:39 | 2017 when she took over as CEO she was talking about 'shareholder value' at the AGM. That was her priority she said in answer to a question from the floor. Five years later on the Ian King interview recently she was again talking about 'shareholder value'. In all that time she has totally failed to produce any. I doubt it is even mentioned in her bonus contract. What a record! | jonjoneil | |
21/2/2022 14:39 | spoole5 lipstick salesperson sounds better :-) | jonjoneil | |
21/2/2022 14:16 | Helps when you aren't run by a lipstick saleswoman . | spoole5 | |
21/2/2022 13:23 | Looks like AZN has another block buster drug on its hands. What a brilliant decision by the CEO to rebuff Pfizer, worth every penny of his salary and more. | essentialinvestor | |
21/2/2022 13:20 | Astra flies - Glaxo dives. What's new? | jonjoneil | |
20/2/2022 17:39 | jonjoneil: Yes I've noticed that with shares, there is often a really steep fall before a prolonged rise begins. So interesting times | netcurtains | |
20/2/2022 15:10 | All this positive news - not good for the share price | jonjoneil | |
20/2/2022 14:17 | Also good article in today’s Mail on Sunday about the fact that the new “game-changing Lots of very positive comments about the vaccine and its growth prospects. The only reason it is not already available is down to supply constraints that have now been addressed. It is predicted that it will rapidly sweep aside the use of the significantly inferior Zostavax (Merck). | spyder | |
19/2/2022 10:52 | Large article in today's Times on the proposed split, they sound very confident, capital markets day on the 28th to reveal more. | krowelet |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions